Methods of Identifying Novel Proteins and Antigens in Cancer Cells

Summary of the technology

- Novel method to identify tumor-specific antigens for cancer immunotherapy.
- Single-Molecule Real-Time (SMRT) Full-Length RNA-Sequencing to identify neoantigens or potential neoantigens as predictive biomarkers and synergistic treatment targets for cancer immunotherapy.
- Method uncovers antigens that would be missed by typical short-read RNA sequencing.

Georgetown University

OVERVIEW

Neoantigens are mainly tumor-specific antigens generated by mutations in tumor cells and are only expressed in tumor cells. Despite the increasing interest in clinical interventions targeting neoantigens, substantial challenges remain to enable a more precise identification of neoantigens that are relevant for patient treatment. Georgetown researchers have developed novel methods of identifying neoantigens or potential neoantigens. The method involves sequencing of isolated long-read messenger RNA (mRNA) through Single-Molecule Real-Time (SMRT) Full-Length RNA-Sequencing.

BACKGROUND

Neoantigens have become compelling targets for cancer immunotherapy due to high levels of immunogenicity and have also been shown to be effective in immune checkpoint blockade therapy. Therefore, neoantigens may serve as predictive biomarkers and synergistic treatment targets in cancer immunotherapy. Neoantigen candidate selection and identification usually rely on the spectra of somatic mutations identified by whole-exome sequencing (WES) coupled with RNA-seq. This approach suffers from a lack of direct experimental evidence of the real presence of predicted epitopes on the cell surface. Georgetown researchers developed methods of identifying neopeptides in abnormal cells, by sequencing isolated long-read messenger RNA (mRNA) through Single-Molecule Real-Time (SMRT) Full-Length RNA-Sequencing.

Benefit

  • Does not require sequencing of economic DNA
  • Allows for the detection of mutations in RNA transcripts
  • Uncovers neo-epitopes that would be missed by short-read RNA sequencing

Market Application

  • Cancer therapies with immune checkpoint inhibitors
  • Diagnostics in cancer
  • Selection of patients for immune checkpoint inhibitor sensitivity and/or resistance

Publications

  • US patent No. 16/322,824
  • Full-length, single-cell RNA-sequencing of human bone marrow subpopulations reveals hidden complexity (DOI: https://doi.org/10.1101/2021.07.28.454226) (link: https://www.biorxiv.org/content/10.1101/2021.07.28.454226v2)
  • Single-Molecule Real-Time (SMRT) Full-Length RNA-Sequencing Reveals Novel and Distinct mRNA Isoforms in Human Bone Marrow Cell Subpopulations (DOI: https://doi.org/10.3390/genes10040253) (link: https://www.mdpi.com/2073-4425/10/4/253)

Related Keywords

  • Cytology, Cancerology, Oncology
  • Diagnostics, Diagnosis
  • Medical Health related
  • cancer
  • rna
  • economic

About Georgetown University

Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.

Georgetown University

Never miss an update from Georgetown University

Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide

Georgetown University

Send a request for information
to Georgetown University

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.

Help

Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support